Summit Therapeutics' stock tumbles again as FDA recommends new trial for lung-cancer drug

By Jaimy Lee

The U.S. regulator's disclosure was more extensive than what the biotech company had announced Sunday

The FDA wants Summit Therapeutics to run another clinical trial for its experimental lung-cancer drug.

Summit Therapeutics' stock tumbled again Tuesday after the Food and Drug Administration said the biotech company should run a new clinical trial for its experimental lung-cancer drug.

Miami-based Summit had been hopeful that the FDA would approve a combination of ivonescimab and chemotherapy as a treatment for patients with EGFR-mutated non-small-cell lung cancer. But the company announced Sunday that the regulator had decided not to approve ivonescimab.

"We believe that the Harmoni study showed a benefit to patients, and it was unfortunate that we couldn't get to an agreement with the FDA to make this available for patients," said Allen Yang, Summit's chief R&D strategy officer.

On Sunday, Summit attributed the FDA's decision to a lack of clinical-trial data showing that the drug could keep people alive longer. That's referred to as overall survival.

But in a letter disclosed by the FDA, the regulator cited other reasons for its decision, in addition to noting there was no statistically significant improvement in overall survival.

The FDA told Summit that it denied approving ivonescimab for three other reasons: the data for progression-free survival didn't reflect how the drug works in the U.S. population, since it was mostly based on patients in China who were first enrolled in the trial; the post hoc analyses for both progression-free survival and overall survival were exploratory rather than confirmatory; and the limited benefit of the drug doesn't outweigh its risks.

The company's plans "probably involve meeting with the FDA," said Urte Gayko, Summit's regulatory chief, though she declined to provide any details about what's next.

Summit's stock (SMMT) was down 10.4% on Tuesday afternoon, the day after its shares closed at their lowest price in two years.

Summit began working on ivonescimab in the U.S. in 2022 after striking a licensing deal with Akeso, the Chinese biotech that discovered the promising new cancer drug. Akeso still has the rights to ivonescimab in China, where it is already approved to treat non-small-cell lung cancer.

Hong Kong-listed shares of Akeso (HK:9926) were down about 3% Tuesday.

The FDA's concerns are notable as global biopharma companies increasingly turn to Chinese biotechs to shore up their pipelines through licensing deals and acquisitions.

Summit's stock has plunged 38.9% so far this year, while the Street SPDR S&P Biotech Exchange-Traded Fund XBI has gained 18.9%.

-Jaimy Lee

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

11-17-26 1559ET

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center